# Pharming Group N.V.: overview PHAR · Nasdaq · CIK 1828316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/phar.md) · [Financials](/companies/phar/financials.md) · [Filings](/companies/phar/filings.md) · [Insiders](/companies/phar/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [199](/filings/0001828316-24-000008.md) | [206](/filings/0001828316-25-000017.md) | [245](/filings/0001828316-26-000015.md) | [297](/filings/0001828316-26-000015.md) | [376](/filings/0001828316-26-000015.md) | | Gross margin | % | [89.4%](/filings/0001828316-24-000008.md) | [91.5%](/filings/0001828316-25-000017.md) | [89.7%](/filings/0001828316-26-000015.md) | [88.1%](/filings/0001828316-26-000015.md) | [87.9%](/filings/0001828316-26-000015.md) | | Operating margin | % | [6.8%](/filings/0001828316-24-000008.md) | [8.9%](/filings/0001828316-25-000017.md) | [(2.2%)](/filings/0001828316-26-000015.md) | [(2.9%)](/filings/0001828316-26-000015.md) | [6.9%](/filings/0001828316-26-000015.md) | | Net margin | % | [8.0%](/filings/0001828316-24-000008.md) | [6.7%](/filings/0001828316-25-000017.md) | [(4.3%)](/filings/0001828316-26-000015.md) | [(4.0%)](/filings/0001828316-26-000015.md) | [0.8%](/filings/0001828316-26-000015.md) | | Diluted EPS | $ per share | [0.02](/filings/0001828316-24-000008.md) | [0.02](/filings/0001828316-25-000017.md) | [(0.02)](/filings/0001828316-26-000015.md) | [(0.02)](/filings/0001828316-26-000015.md) | [0.00](/filings/0001828316-26-000015.md) | | Free cash flow | $m | [27.1](/filings/0001828316-24-000008.md) | [21.1](/filings/0001828316-25-000017.md) | [(18.7)](/filings/0001828316-26-000015.md) | [(2.6)](/filings/0001828316-26-000015.md) | [54.0](/filings/0001828316-26-000015.md) | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers; Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/phar/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MAC Alpha Capital Management, LP](/funds/2111003.md) | 2026-06-30 | $2.9m | 2,148,144 | | New +2,148,144 | | [Silverberg Bernstein Capital Management LLC](/funds/2007880.md) | 2026-06-30 | $577.1k | 41,547 | | Reduced −3,200 | | [Crossmark Global Holdings, Inc.](/funds/1539204.md) | 2026-06-30 | $169.0k | 12,463 | | New +12,463 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $162.3k | 11,972 | | Added +1,783 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $159.7k | 11,500 | | Added +11 | | [SmartHarvest Portfolios, LLC](/funds/2066604.md) | 2026-06-30 | $144.7k | 10,415 | | Reduced −382 | | [Knoll Capital Management, LLC](/funds/1325083.md) | 2026-06-30 | $56.8k | 4,091 | | Added +34 | | [Silver Grove Financial Group, Inc.](/funds/2111172.md) | 2026-06-30 | $14.9k | 1,071 | | New +1,071 | | [Nalls Sherbakoff Group, LLC](/funds/1767500.md) | 2026-06-30 | $12.1k | 870 | | Not compared | | [Global Retirement Partners, LLC](/funds/1749744.md) | 2026-06-30 | $6.3k | 456 | | Not compared | ## Recent filings [All 146 filings](/companies/phar/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:11 ET | [6-K](/filings/0001828316-26-000049.md) | Report of a foreign private issuer, period 2026-10-27 | 0001828316-26-000049 | | 2026-10-22 | 07:06 ET | [6-K](/filings/0001828316-26-000047.md) | Report of a foreign private issuer, period 2026-10-22 | 0001828316-26-000047 | | 2026-10-14 | 06:03 ET | [6-K](/filings/0001828316-26-000045.md) | Report of a foreign private issuer, period 2026-10-14 | 0001828316-26-000045 | | 2026-09-29 | 06:40 ET | [6-K](/filings/0001828316-26-000043.md) | Report of a foreign private issuer, period 2026-09-29 | 0001828316-26-000043 | | 2026-09-25 | 11:12 ET | [6-K](/filings/0001828316-26-000041.md) | Report of a foreign private issuer, period 2026-09-25 | 0001828316-26-000041 | | 2026-09-22 | 06:02 ET | [6-K](/filings/0001828316-26-000039.md) | Report of a foreign private issuer, period 2026-09-22 | 0001828316-26-000039 | | 2026-09-11 | 14:59 ET | [6-K](/filings/0001828316-26-000037.md) | Report of a foreign private issuer, period 2026-09-11 | 0001828316-26-000037 | | 2026-08-13 | 06:06 ET | [6-K](/filings/0001828316-26-000035.md) | Report of a foreign private issuer, period 2026-08-13 | 0001828316-26-000035 | | 2026-07-30 | 06:07 ET | [6-K](/filings/0001828316-26-000033.md) | Report of a foreign private issuer, period 2026-07-30 | 0001828316-26-000033 | | 2026-06-04 | 06:09 ET | [6-K](/filings/0001828316-26-000031.md) | Report of a foreign private issuer, period 2026-06-04 | 0001828316-26-000031 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001828316-26-000015.md), filed Apr 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1828316 - Tickers: PHAR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: P7 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:12 ET. No prices; not investment advice.